Researchers are launching a clinical trial to test whether eating only between 8 AM and 6 PM on a Mediterranean diet works as well as weight-loss medication for improving liver health in people with obesity and metabolic disease. The 6-month study will compare these two approaches in 70 adults with liver damage, measuring changes in liver stiffness as the main outcome. According to Gram Research analysis, this head-to-head comparison will help determine if dietary timing could offer an effective alternative to medication for protecting the liver.
Researchers are testing whether eating only during a 10-hour window combined with a Mediterranean diet works as well as weight-loss medication for improving liver health in people with diabetes, obesity, or high blood pressure. This new study will compare these two approaches in 70 adults with liver damage over 6 months. According to Gram Research analysis, the trial aims to determine if changing when and what you eat could be just as effective as taking medication for protecting your liver from serious disease.
Key Statistics
A 2026 randomized controlled trial protocol published in BMJ Open will compare early time-restricted eating with a Mediterranean diet to naltrexone/bupropion medication in 70 overweight adults with liver fibrosis and cardiometabolic risk factors.
The MEDFAST trial will measure liver stiffness in participants with moderate to severe fibrosis (readings between 7.0 and 13.6 kPa) over 6 months to determine which approach—dietary intervention or weight-loss medication—more effectively improves liver health.
The study targets adults aged 18-75 years with type 2 diabetes, hypertension, dyslipidemia, or obesity who have documented liver fibrosis, representing a population at high risk for progressive liver disease.
The Quick Take
- What they studied: Whether eating only between 8 AM and 6 PM while following a Mediterranean diet works as well as a weight-loss medication for improving liver health in people with weight and metabolic problems.
- Who participated: 70 adults aged 18-75 years who are overweight and have conditions like type 2 diabetes, high blood pressure, high cholesterol, or obesity, plus signs of liver damage.
- Key finding: This is a study protocol (the plan for the research), not yet completed results. The trial will measure liver stiffness—a sign of liver damage—to see if the eating schedule or medication works better over 6 months.
- What it means for you: If the diet approach works as well as medication, it could offer people a non-medication option for protecting their liver. However, results won’t be available until the study finishes, so don’t change your treatment based on this yet.
The Research Details
This is a randomized controlled trial, which is one of the strongest types of medical research. Researchers will randomly assign 70 people into two groups: one group will eat only between 8 AM and 6 PM while following a Mediterranean diet (lots of vegetables, fish, olive oil, whole grains), and the other group will take a weight-loss medication called naltrexone/bupropion. Both groups will be followed for 6 months to see which approach better improves liver health.
The study focuses on people with metabolic dysfunction-associated steatotic liver disease (MASLD)—a condition where fat builds up in the liver, often linked to obesity and diabetes. This condition can get worse over time and lead to serious liver damage. The researchers will measure liver stiffness using a special ultrasound technique called transient elastography, which shows how much scarring or damage the liver has.
This comparison is important because while weight-loss medication has become popular, we don’t have good evidence comparing it directly to dietary changes. The study will also track weight loss, heart health markers, quality of life, and how well people stick with each approach.
Many people with obesity and diabetes develop liver disease without knowing it. Weight loss is the main treatment, but it’s unclear whether diet changes or medication work better. This study matters because it directly compares two realistic options people might choose, which will help doctors and patients make better decisions about treatment.
This is a well-designed study being conducted in a hospital setting with proper ethical approval. The researchers will use objective measurements (liver stiffness testing) rather than relying on patient reports. However, this is the study protocol (the plan), not the results yet, so we don’t know the actual outcomes. The relatively small sample size of 70 people means results should be confirmed in larger studies before making major changes to treatment guidelines.
What the Results Show
This article describes the study plan, not actual results. The researchers have not yet completed the trial or collected data. The main goal will be to measure changes in liver stiffness from the start to 6 months in both groups and compare which approach produces better improvements.
The study will measure liver stiffness using transient elastography, a painless ultrasound technique that shows how much scarring or damage the liver has. People in the study have moderate to severe liver fibrosis (stiffness measurements between 7.0 and 13.6 kPa on the scale used). The researchers will see if either the eating schedule or medication reduces this stiffness more effectively.
Because this is a randomized controlled trial, the researchers will randomly assign people to each group to make sure the groups are similar at the start. This helps ensure that any differences in results are due to the treatment, not differences between the people in each group.
Beyond liver stiffness, the study will also measure: how much fat is in the liver (liver steatosis), weight loss, changes in body composition (muscle vs. fat), heart disease risk factors like blood pressure and cholesterol, quality of life, how satisfied people are with their treatment, and how well people stick with their assigned approach. These secondary measurements will give a fuller picture of how each approach affects overall health.
Previous research shows that weight loss improves liver health in people with fatty liver disease. Some studies suggest that time-restricted eating and Mediterranean diets separately can help with weight loss and liver health. However, this is the first study to directly compare an eating schedule combined with a Mediterranean diet against a weight-loss medication in people with liver damage. This head-to-head comparison fills an important gap in medical knowledge.
This is a study protocol, so actual results aren’t available yet. When results do come out, the relatively small sample size (70 people) means findings should be confirmed in larger studies. The 6-month timeframe is relatively short for measuring liver disease changes. The study only includes people with moderate to severe liver fibrosis, so results may not apply to people with milder liver disease. Additionally, people who choose to participate may be different from the general population, which could affect how well results apply to everyone.
The Bottom Line
This study is still in progress, so there are no new recommendations yet. Current medical evidence supports weight loss through diet, exercise, or medication for people with fatty liver disease. If you have liver disease, diabetes, or obesity, talk with your doctor about which approach might work best for you. Do not change your current treatment based on this study protocol alone.
People with obesity, type 2 diabetes, high blood pressure, or high cholesterol who also have liver damage should pay attention to this research. People interested in non-medication approaches to weight loss and health may find the results relevant. Healthcare providers treating metabolic disease will want to see the results to guide treatment decisions. People without liver disease or metabolic problems don’t need to change anything based on this study.
The study is expected to take 6 months to complete data collection. Results will likely be published 6-12 months after data collection ends, so expect to see findings sometime in 2027 or 2028. Even after publication, it may take additional time for doctors to incorporate findings into treatment guidelines.
Frequently Asked Questions
Can eating during a shorter time window help fix a fatty liver?
Time-restricted eating may help with weight loss, which improves fatty liver disease. This new trial will test whether eating only between 8 AM-6 PM combined with a Mediterranean diet works as well as medication for improving liver health over 6 months.
Is the Mediterranean diet better than weight loss pills for liver disease?
This study will directly compare them for the first time. Current evidence supports weight loss through either approach, but we don’t know which works better for liver fibrosis specifically. Results will be available in 2027-2028.
Who should try early time-restricted eating for liver health?
People with obesity, diabetes, or high blood pressure who also have liver damage may benefit, but talk with your doctor first. This trial is specifically testing people with moderate to severe liver fibrosis, not mild cases.
How long does it take to see liver improvements from diet changes?
This study measures changes over 6 months. Real-world improvements may take longer. Your doctor can monitor liver health with blood tests and ultrasound to track progress over time.
What is metabolic dysfunction-associated steatotic liver disease?
It’s fatty liver disease linked to obesity, diabetes, and metabolic problems. Fat builds up in liver cells, potentially causing scarring and damage. Weight loss is the main treatment to prevent serious complications.
Want to Apply This Research?
- Track eating window compliance (did you eat only between 8 AM-6 PM?) and weight weekly. If following the Mediterranean diet, log meals to ensure adherence to the dietary pattern.
- Set phone reminders for your 8 AM eating window start and 6 PM eating window end. Use the app to plan Mediterranean-style meals in advance and track which foods you’re eating during your allowed eating hours.
- Monitor weekly weight trends, eating window adherence percentage, and energy levels throughout the day. If doing this under medical supervision, share monthly summaries with your healthcare provider to track progress toward liver health improvements.
This article describes a research study protocol (the plan for a trial), not completed results. The study has not yet been conducted or published with findings. Do not change your medical treatment based on this protocol. If you have liver disease, diabetes, obesity, or related conditions, consult your healthcare provider before making dietary or medication changes. This information is for educational purposes only and should not replace professional medical advice. Always work with your doctor to develop a treatment plan appropriate for your individual health situation.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.